NORMAL SITUATION

NEUPHARMA

Export PDF

Financial year 2022 · closed on 31/12/2022

Net result

43,4 k €

+382.6% YoY

Gross margin

157,6 k €

+19.7% YoY

Equity

298,6 k €

+17.0% YoY

Workforce

2,4 ETP

-7.7% YoY

Company — Normal situation.

What does NEUPHARMA do?

NEUPHARMA is a company registered in Belgium. It employs on average 2,4 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0840.662.376

Legal form

Private company with limited liability

Contributed capital

49 868,62 €

Latest accounts

31/12/2022

Average workforce

2,4 ETP

Joint committees (1)

Signals

ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 12 financial years

	2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011
Income statement
Gross margin	157,6 k €	+19.7%	131,7 k €	-10.4%	147 k €	+16.5%	126,2 k €	-19.9%	157,5 k €	+35.7%	116,1 k €	-16.9%	139,7 k €	-25.7%	188,1 k €	+6.9%	175,9 k €	+34.9%	130,4 k €	+32.2%	98,6 k €	-15.7%	117 k €
EBITDA	65,5 k €	+117%	30,2 k €	+144%	12,4 k €	+2.8%	12,1 k €	-74.5%	47,3 k €	+252%	13,4 k €	-63.5%	36,8 k €	-56.7%	85 k €	+19.3%	71,2 k €	+87.4%	38 k €	+405%	7,5 k €	+119%	-39,1 k €
Operating result	59,7 k €	+416%	11,6 k €	+240%	-8,2 k €	-12.1%	-7,3 k €	-127%	27,5 k €	+468%	-7,5 k €	-157%	13,2 k €	-73.6%	49,9 k €	+4.3%	47,9 k €	+223%	14,8 k €	+195%	-15,6 k €	+66.6%	-46,6 k €
Net result	43,4 k €	+383%	9 k €	+183%	-10,8 k €	-10.3%	-9,8 k €	-174%	13,3 k €	-63.0%	35,9 k €	+824%	3,9 k €	-88.8%	34,6 k €	+366%	-13 k €	-157%	22,8 k €	+428%	-7 k €	-107%	104,5 k €
Balance sheet
Equity	298,6 k €	+17.0%	255,3 k €	+3.6%	246,3 k €	-4.2%	257,1 k €	-3.7%	266,9 k €	+5.2%	253,6 k €	-17.6%	307,6 k €	+1.3%	303,8 k €	+5.8%	287,2 k €	-18.0%	350,2 k €	-7.8%	380 k €	-1.8%	386,9 k €
Total assets	459,1 k €	+18.0%	389,2 k €	-5.2%	410,7 k €	+4.9%	391,6 k €	-10.0%	435,1 k €	-15.3%	514 k €	-17.6%	624,1 k €	-0.4%	626,3 k €	-10.1%	697 k €	-3.5%	722,4 k €	+0.8%	716,8 k €	-11.3%	808 k €
Cash	144,8 k €	-6.8%	155,4 k €	+7.8%	144,2 k €	+46.5%	98,4 k €	-18.9%	121,4 k €	-35.8%	189,2 k €	-10.0%	210,1 k €	+4.7%	200,6 k €	-12.6%	229,6 k €	+23.4%	186 k €	+84.2%	101 k €	-59.7%	250,8 k €
Debts	160,1 k €	+19.5%	133,9 k €	-18.6%	164,5 k €	+22.3%	134,5 k €	-20.1%	168,3 k €	-35.4%	260,5 k €	-8.8%	285,6 k €	+9.5%	260,8 k €	-16.8%	313,6 k €	+28.9%	243,3 k €	+18.3%	205,7 k €	-27.9%	285,2 k €
Other
Workforce	2,4 ETP	-7.7%	2,6 ETP	-23.5%	3,4 ETP	+21.4%	2,8 ETP	0.0%	2,8 ETP	+3.7%	2,7 ETP	0.0%	2,7 ETP	0.0%	2,7 ETP	+3.8%	2,6 ETP	+13.0%	2,3 ETP	0.0%	2,3 ETP	+43.7%	1,6 ETP

Governance

Board of directors

Seen on filing of 31/12/2022 · 4 active · 6 ended

Active mandates

Anne BAELEN

Director · since 31 octobre 2022

Active

Jean HENIN

Director · since 10 novembre 2011 · until 31 octobre 2022

Active

Jean-Paul BROHEE

Director · since 10 novembre 2011 · until 31 octobre 2022

Active

Christine DEGARDIN

Associate · until 31 octobre 2022

Active

Ended mandates

CHRISTINE DEGARDIN

Associate

Ended

JEAN HENIN

Director

Ended

JEAN HENIN

Manager

Ended

JEAN PAUL BROHEE

Director

Ended

Annual accounts

Full financial information

	2022	2021	2020	2019	2018	2017
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2022	01/01/2021	01/01/2020	01/01/2019	01/01/2018	01/01/2017
Closing of the financial year	31/12/2022	31/12/2021	31/12/2020	31/12/2019	31/12/2018	31/12/2017
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	06/07/2023	25/08/2022	30/09/2021	24/10/2020	20/08/2019	20/08/2018
General meeting	27/05/2023	08/06/2022	14/09/2021	02/10/2020	29/07/2019	06/08/2018
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

12 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2022	27/05/2023	06/07/2023	French	PDF
Abridged model	31/12/2021	08/06/2022	25/08/2022	French	PDF
Abridged model	31/12/2020	14/09/2021	30/09/2021	French	PDF
Abridged model	31/12/2019	02/10/2020	24/10/2020	French	PDF
Abridged model	31/12/2018	29/07/2019	20/08/2019	French	PDF
Abridged model	31/12/2017	06/08/2018	20/08/2018	French	PDF
Abridged model	31/12/2016	28/09/2017	29/09/2017	French	PDF
Abridged model	31/12/2015	21/06/2016	24/08/2016	French	PDF
Abridged model	31/12/2014	19/11/2015	30/11/2015	French	PDF
Abridged model	31/12/2013	26/09/2014	13/10/2014	French	PDF
Abridged model	31/12/2012	19/09/2013	23/09/2013	French	PDF
Abridged model	31/12/2011	08/10/2012	11/10/2012	French	PDF

Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2022 · 4 active · 6 ended

Active mandates

Anne BAELEN

Director · since 31 octobre 2022

Active

Jean HENIN

Director · since 10 novembre 2011 · until 31 octobre 2022

Active

Jean-Paul BROHEE

Director · since 10 novembre 2011 · until 31 octobre 2022

Active

Christine DEGARDIN

Associate · until 31 octobre 2022

Active

Ended mandates

CHRISTINE DEGARDIN

Associate

Ended

JEAN HENIN

Director

Ended

JEAN HENIN

Manager

Ended

JEAN PAUL BROHEE

Director

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Dissolution11/10/2023
RUBRIQUE FIN (CESSATION, ANNULATION CESSATION, NULLITE, CONC, REORGANISATION JUDICIAIRE, ETC...) - RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
PDF
Restructuring28/02/2023
RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2022
Annual accounts 202243,4 k €↑
2021
Annual accounts 20219 k €↑
2020
Annual accounts 2020-10,8 k €↓
2019
Annual accounts 2019-9,8 k €↓
2018
Annual accounts 201813,3 k €↓
2017
Annual accounts 201735,9 k €↑
2016
Annual accounts 20163,9 k €↓
2015
Annual accounts 201534,6 k €↑
2014
Annual accounts 2014-13 k €↓
2013
Annual accounts 201322,8 k €↑
2012
Annual accounts 2012-7 k €↓
2011
Annual accounts 2011104,5 k €

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

NEUPHARMA

Overview

What does NEUPHARMA do?

Trend over 12 financial years

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline